सभी अध्ययन
आमंत्रण द्वारा नामांकनचरण3हस्तक्षेपात्मक

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

This research study is for adults living with specific muscle conditions, such as myositis, dermatomyositis, or polymyositis. We are looking into a new medication called efgartigimod, given as an injection under the skin. The main goal is to understand if this medicine is safe and effective for long-term use in people who have already tried it in a previous study. Participants will receive the medicine for up to 51 months, and then their health will be checked for two more months after they stop taking it. This helps researchers learn more about how the medicine works over time and if it can improve the lives of those with these conditions.

एक नजर में

स्थिति
आमंत्रण द्वारा नामांकन
चरण
चरण3
प्रायोजक
argenx
नामांकन लक्ष्य
240
प्रारंभ
12 Sep 2023
अनुमानित पूर्णता
01 सितम्बर 2028

यह अध्ययन किस बारे में है?

This study is investigating a new medication called efgartigimod, which is given as an injection under the skin, for adults with certain muscle diseases. These diseases are sometimes called idiopathic inflammatory myopathies, which include conditions like dermatomyositis, polymyositis, and immune-mediated necrotizing myopathy. These conditions can cause muscle weakness and other symptoms.

The main purpose of this research is to see how safe and helpful efgartigimod is over a long period. All participants in this study would have already taken part in a previous study for efgartigimod. This follow-up study helps doctors understand the long-term effects of the medication.

By taking part, you would help doctors learn more about this medication. This knowledge could potentially lead to better treatments for people with these challenging muscle conditions in the future.

मुख्य निष्कर्ष

  • This study evaluates a new medication called efgartigimod for muscle conditions.
  • It's a long-term study for adults who participated in a previous trial.
  • The medication is given as an injection under the skin.
  • The main goals are to check the medication's long-term safety and effectiveness.
  • Participation helps future patients with these conditions.

कौन पात्र हो सकता है?

To join this study, you must be an adult aged 18 or older and have previously taken part in a specific trial called ARGX-113-2007. You should be able to understand the study details and give your official consent to participate.

There are also some reasons why you might not be able to join. For example, if you plan to have major surgery during the study, or if you've developed a serious medical condition since the last study that the doctors think would make it risky for you to participate or affect the study results. You also can't take part if you are allergic to the study medicine or any of its ingredients, or if you've developed any new or returning cancer (other than a common type of skin cancer).

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. क्या आप 18 वर्ष या उससे अधिक आयु के हैं?
  2. Did you previously take part in the ARGX-113-2007 study?
  3. Are you able to follow study instructions and give your informed consent?
  4. Are you not planning to have major surgery during the study?
  5. Are you not allergic to the study drug or its ingredients?
  6. Have you not developed any new cancer (other than certain skin cancers)?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to join this study, you will receive the study medication, efgartigimod, as an injection under your skin regularly for up to 51 months (about 4 years and 3 months). During this time, you will have regular visits to the clinic so doctors can monitor your health and how the medication is affecting you. After you finish taking the medication, there will be a follow-up period of about 8 weeks (56 days) where your health will continue to be checked to ensure your safety. The total duration of your involvement could be up to 53 months, including the treatment and follow-up periods.

संभावित जोखिम और लाभ

Taking part in this study may offer potential benefits, such as continued access to a new medication for your condition and close medical monitoring. However, there are potential risks, including side effects from the medication or the need for frequent clinic visits. You can withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (92)

  • Neuromuscular Clinical and Research Center - Neurology
    सत्यापित पोस्टकोड
    फीनिक्स, संयुक्त राज्य अमेरिका
  • Attune Health Research, Inc
    सत्यापित पोस्टकोड
    बेवर्ली हिल्स, संयुक्त राज्य अमेरिका
  • UCI Health - ALS and Neuromuscular Center - Neurology
    सत्यापित पोस्टकोड
    ऑरेंज, संयुक्त राज्य अमेरिका
  • UCSF Health - ALS and Neurodegenerative Disease Center - Dermatology
    सत्यापित पोस्टकोड
    सैन फ्रांसिस्को, संयुक्त राज्य अमेरिका
  • Yale Cancer Center-Yale University School Of Medicine
    सत्यापित पोस्टकोड
    न्यू हेवन, संयुक्त राज्य अमेरिका
  • UF Health - Rheumatology Medical Specialties Medical Plaza
    सत्यापित पोस्टकोड
    गेन्सविल, संयुक्त राज्य अमेरिका
  • Mayo Clinic - Florida - Neurology
    सत्यापित पोस्टकोड
    जैक्सनविल, संयुक्त राज्य अमेरिका
  • University of South Florida (USF) - Morsani Center (USF Health Carol and Frank Morsani Center for Advanced Healthcare)
    सत्यापित पोस्टकोड
    टाम्पा, संयुक्त राज्य अमेरिका
  • Emory Healthcare - Emory Clinic - Rheumatology
    सत्यापित पोस्टकोड
    अटलांटा, संयुक्त राज्य अमेरिका
  • Northwestern Medicine - Northwestern Memorial Hospital
    सत्यापित पोस्टकोड
    शिकागो, संयुक्त राज्य अमेरिका
  • John Hopkins Medicine - Johns Hopkins Myositis Center
    सत्यापित पोस्टकोड
    बाल्टीमोर, संयुक्त राज्य अमेरिका
  • Northwell Health Physician Partners Rheumatology
    सत्यापित पोस्टकोड
    Great Neck, United States

सामान्य प्रश्न

What is efgartigimod?

Efgartigimod is the name of the study medication being tested for treating certain muscle conditions.

What medical conditions are being studied?

The study focuses on adult patients with specific muscle conditions, such as myositis, dermatomyositis, and polymyositis.

How is the study medicine given?

The study medicine is given as an injection under the skin.

मैं अध्ययन में कितने समय तक रहूँगा?

You could be in the study for up to 51 months receiving the treatment, plus a two-month follow-up period, making the total up to roughly 4 and a half years.

क्या मैं किसी भी समय अध्ययन छोड़ सकता हूँ?

Yes, you are free to leave the study at any point without having to give a reason and without your medical care being affected.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "A Study to Assess the Long-term Safety and Efficacy of a Sub…यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.